Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16878196 | 0.97 | CXCR4 (0.35) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1792036 | 0.92 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL16878055 | 0.92 | CXCR4 (0.35) | CXCR4SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21360053 | 0.89 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16877626 | 0.89 | CXCR4 (0.40) | CXCR4SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16195650 | 0.89 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16877555 | 0.86 | CXCR4 (0.42) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL14759970 | 0.86 | CXCR4 (0.35) | CXCR4SMN1; SMN2 | |
| SCHEMBL932275 | 0.86 | CXCR4 (0.35) | CXCR4SMN1; SMN2 | |
| SCHEMBL16878194 | 0.85 | CXCR4 (0.39) | CXCR4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | claimed |
| EP-4646263-A1 | SPRK1 INHIBITORS AND METHODS OF USE | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | claimed |
| EP-4590672-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Merck Sharp & Dohme LLC (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2025111409-A1 | HETEROCYCLIC COMPOUNDS OF FORMULA (I) FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY VIA MODULATION OF SMN2 SPLICING | BIOGEN MA INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119866329-A | Heterocyclic compounds for the treatment of huntington's disease | 渤健马萨诸塞州股份有限公司 | 2025-04-22 | — | — | CN | claimed |
| EP-4526292-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2024155864-A1 | SPRK1 INHIBITORS AND METHODS OF USE | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | WO | claimed |
| US-20240124451-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-04-18 | — | — | US | claimed |
| WO-2024064245-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | WO | claimed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | MERCK SHARP & DOHME CORP. | 2020-09-17 | — | — | US | claimed |
| EP-3430013-A1 | CARBAPENEM COMPOUNDS | Orchid Pharma Limited (IN) | 2019-01-23 | — | — | EP | claimed |
| WO-2017158616-A1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD. (IN) | 2017-09-21 | — | — | WO | claimed |
| EP-2528910-B1 | 5-Alkynyl pyrimidines ahd their use as kinase inhibitors. | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | claimed |
| US-8618111-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| EP-2528910-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | claimed |
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| WO-2011092197-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | claimed |
| EP-0566069-A1 | Tachykinin receptor antagonists, isoquinolones and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | MKI67, CCNA1, CCNT1 | CXCR4 662/4885SMN1; SMN2 529/4885ALDH1A1 79/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CXCR4 4426/4885SMN1; SMN2 18/4885ALDH1A1 2917/4885 |
| US-20240124451-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NLRP3, FABP3, NOD2 | CXCR4 2230/4885SMN1; SMN2 3088/4885ALDH1A1 4488/4885 |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | GSK3B, GSK3A, GNE | CXCR4 988/4885SMN1; SMN2 1076/4885ALDH1A1 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.